The estimated Net Worth of Carrie Brownstein is at least $601 Tysiąc dollars as of 4 October 2023. Carrie Brownstein owns over 10,628 units of Shattuck Labs stock worth over $394,205 and over the last 3 years Carrie sold STTK stock worth over $207,246.
Sign up
Carrie Brownstein STTK stock SEC Form 4 insiders trading
Carrie has made over 1 trades of the Shattuck Labs stock since 2023, according to the Form 4 filled with the SEC. Most recently Carrie sold 10,628 units of STTK stock worth $207,246 on 4 October 2023.
The largest trade Carrie's ever made was selling 10,628 units of Shattuck Labs stock on 4 October 2023 worth over $207,246. On average, Carrie trades about 1,518 units every 0 days since 2021. As of 4 October 2023 Carrie still owns at least 105,685 units of Shattuck Labs stock.
You can see the complete history of Carrie Brownstein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Carrie Brownstein's mailing address?
Carrie's mailing address filed with the SEC is C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN, TX, 78701.
Insiders trading at Shattuck Labs
Over the last 4 years, insiders at Shattuck Labs have traded over $14,634,250 worth of Shattuck Labs stock and bought 3,526,605 units worth $60,008,520 . The most active insiders traders include Group, Llc Green Jeremy Red..., Clay B Siegall oraz Josiah Hornblower. On average, Shattuck Labs executives and independent directors trade stock every 25 days with the average trade being worth of $300,381. The most recent stock trade was executed by Tyler Brous on 27 June 2024, trading 8,416 units of STTK stock currently worth $32,738.
What does Shattuck Labs do?
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
What does Shattuck Labs's logo look like?
Complete history of Carrie Brownstein stock trades at Zentalis Pharmaceuticals, Llc i Shattuck Labs
Shattuck Labs executives and stock owners
Shattuck Labs executives and other stock owners filed with the SEC include:
-
Dr. Arundathy Nirmalini Pandite M.B.A., M.D.,
Chief Medical Officer -
Dr. Arundathy Nirmalini Pandite,
Chief Medical Officer -
Dr. Taylor H. Schreiber M.D., Ph.D.,
Co-Founder, CEO & Director -
Casi DeYoung,
Chief Bus. Officer -
Dr. Taylor H. Schreiber,
Co-Founder, CEO & Director -
Josiah C. Hornblower,
Co-Founder & Exec. Chairman -
Erin Ator Thomson J.D.,
Gen. Counsel -
Dr. Abhinav A. Shukla Ph.D.,
Chief Technical Officer -
Dr. Thomas Lampkin Pharm.D.,
Head of Regulatory Affairs -
Conor Richardson,
Director of Fin. -
Andrew R. Neill M.B.A.,
VP of Fin. & Corp. Strategy -
Amy Kate Sasser,
-
Michael Stewart Lee,
Director -
Arundathy N. Pandite,
Chief Medical Officer -
Casi De Young,
Chief Business Officer -
Abhinav A. Shukla,
Chief Technical Officer -
Group, Llc Green Jeremy Red...,
-
Taylor Schreiber,
Chief Executive Officer -
Erin Ator Thomson,
General Counsel -
Neil W Gibson,
-
Andrew R Neill,
Chief Financial Officer -
George Golumbeski,
-
Josiah Hornblower,
Director -
Tyler Brous,
-
Stephen Stout,
See Remarks -
Carrie Brownstein,
-
Clay B Siegall,